Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Digging into the Phase 3 NORSE TWO clinical trial of LYTENAVA (bevacizumab-vikg) in patients with wet age-related macular degeneration.

Ticker(s): OTLK, RHHBY

Who's the expert?

Institution: Iowa Retina Consultants

Board Certified Ophthalmologist with Iowa Retina Consultants
Currently manages 1000 patients with Wet AMD.

Interview Goal

To discuss the standard of care and the potential of ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) being developed by Outlook Therapeutics.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.